Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | BTK | Q06187 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 1.00 |
| ▸ | DHODH | Q02127 | 18/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51144 | 1.00 | MEN1 (1.00) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL29394998 | 1.00 | MEN1 (1.00) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL51142 | 1.00 | MEN1 (1.00) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL5914885 | 0.89 | ALDH1A1 (0.80) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL5914888 | 0.89 | ALDH1A1 (0.80) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL28057335 | 0.84 | MEN1 (0.70) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL5914906 | 0.82 | MEN1 (0.70) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL5914905 | 0.82 | MEN1 (0.70) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL5914890 | 0.79 | DHODH (0.70) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL5914891 | 0.79 | DHODH (0.70) | MEN1ALDH1A1KMT2ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9820987-B2 | Modulator compounds of drug resistance in epithelial tumor cells | BIONSIL S.R.L. IN LIQUIDAZIONE (IT) | 2017-11-21 | — | — | US | claimed |
| US-20160251614-A1 | CELL CULTURE MEDIUM AND BIOPROCESS OPTIMIZATION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2016-09-01 | — | — | US | claimed |
| US-20150111953-A1 | Modulator Compounds of Drug Resistance in Epithelial Tumor Cells | BIONSIL S.R.L. IN LIQUIDAZIONE (IT) | 2015-04-23 | — | — | US | claimed |
| US-8129356-B2 | Bmx mediated signal transduction in irradiated vascular endothelium | VANDERBILT UNIVERSITY (US) | 2012-03-06 | — | — | US | claimed |
| US-20090136487-A1 | BMX MEDIATED SIGNAL TRANSDUCTION IN IRRADIATED VASCULAR ENDOTHELIUM | VANDERBILT UNIVERSITY | 2009-05-28 | — | — | US | claimed |
| US-20040127453-A1 | Method for treating diseases associated with abnormal kinase activity | SUPERGEN, INC. | 2004-07-01 | — | — | US | claimed |
| EP-3645001-B1 | MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF | G1 THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240199581-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4384162-A1 | COMPOSITIONS AND METHODS FOR EXTENDED RELEASE CROMAKALIM THERAPY | Qlaris Bio, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-20240158418-A1 | EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS | C4 THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2024097980-A1 | RET-LDD PROTEIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024097989-A1 | RET-LDD PROTEIN DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-05-10 | — | — | WO | disclosed |
| US-6294575-B1 | FOR THERAPY OF ALLERGY BY ADMINISTERING INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | PARKER HUGHES INSTITUTE | 2001-09-25 | — | — | US | disclosed |
| US-6248790-B1 | Treatment of inflammation with 2,4,6-trihydroxy-alpha-rho-methoxyphenylacetophenone, or its pharmaceutically acceptable derivatives | PARKER HUGHES INSTITUTE | 2001-06-19 | — | — | US | disclosed |
| WO-2001041754-A2 | INHIBITORS OF COLLAGEN-INDUCED PLATELET AGGREGATION | PARKER HUGHES INSTITUTE (US) | 2001-06-14 | — | — | WO | disclosed |
| US-6221900-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK). | HUGHES INSTITUTE | 2001-04-24 | — | — | US | disclosed |
| EP-1071658-A2 | BTK INHIBITORS AND METHODS FOR THEIR IDENTIFICATION AND USE | Parker Hughes Institute (US) | 2001-01-31 | — | — | EP | disclosed |
| US-6160010-A | BTK inhibitors and methods for their identification and use | PARKER HUGHES INSTITUTE (US) | 2000-12-12 | — | — | US | disclosed |
| WO-1999054286-A2 | BTK INHIBITORS AND METHODS FOR THEIR IDENTIFICATION AND USE | PARKER HUGHES INSTITUTE (US) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199581-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | BRAF, NRAS, KRAS | MEN1 594/4885ALDH1A1 1471/4885KMT2A 1520/4885 |
| US-20240158418-A1 | EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS | EGFR, ERBB2, ERBB3 | MEN1 1683/4885ALDH1A1 3277/4885KMT2A 738/4885 |
| US-20150111953-A1 | Modulator Compounds of Drug Resistance in Epithelial Tumor Cells | BTK, PRKDC, PCLAF | MEN1 3314/4885ALDH1A1 4313/4885KMT2A 1708/4885 |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | MEN1 1031/4885ALDH1A1 2819/4885KMT2A 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.